Comparative Pharmacology
Head-to-head clinical analysis: FUROXONE versus NITROFURAZONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUROXONE versus NITROFURAZONE.
FUROXONE vs NITROFURAZONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Furazolidone is a nitrofuran antimicrobial that inhibits bacterial monoamine oxidase and disrupts bacterial DNA synthesis by undergoing reduction by bacterial nitroreductases to reactive intermediates that cause DNA cross-linking and damage.
Nitrofurazone is a nitrofuran antibacterial agent that acts by inhibiting bacterial DNA synthesis and repair through reductive activation of the nitrofuran group. It disrupts bacterial enzymes involved in carbohydrate metabolism and inhibits acetylcoenzyme A formation.
100 mg orally four times daily
Nitrofurazone is not systemically administered; it is used topically. For topical application, apply a thin layer to the affected area 1-2 times daily, as directed by a physician.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours; clinically, this supports dosing every 6 hours for sustained antibacterial effect.
0.3–0.5 hours (rapid metabolism and excretion; clinically short duration requires frequent dosing for local infections).
Primarily renal (approximately 65%) as unchanged drug; biliary/fecal excretion accounts for about 35%.
Renal: ~80% (glomerular filtration and tubular secretion); Fecal: ~10% (biliary excretion); Hepatic metabolism: ~10%.
Category C
Category C
Antibacterial/Antiprotozoal
Antibacterial